AAAAAA
Results:
1-22
|
Results: 22
Authors:
Stuart, JWTC
Wensing, AMJ
Kovacs, C
Righart, M
de Jong, D
Kaye, S
Schuurman, R
Visser, CJT
Boucher, CAB
Citation: Jwtc. Stuart et al., Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance, J ACQ IMM D, 28(2), 2001, pp. 105-113
Authors:
van Elden, LJR
van Essen, GA
Boucher, CAB
van Loon, AM
Nijhuis, M
Schipper, P
Verheij, TJM
Hoepelman, IM
Citation: Ljr. Van Elden et al., Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice, BR J GEN PR, 51(469), 2001, pp. 630-634
Authors:
Wensing, AMJ
Reedijk, M
Richter, C
Boucher, CAB
Borleffs, JCC
Citation: Amj. Wensing et al., Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels, AIDS, 15(16), 2001, pp. 2191-2193
Authors:
Mascolini, M
Wensing, AMJ
Boucher, CAB
Citation: M. Mascolini et al., HIV resistance assay results and their effect on therapeutic decisions, AIDS, 15(1), 2001, pp. 124-126
Authors:
van Esser, JWJ
Niesters, HGM
Thijsen, SFT
Meijer, E
Osterhaus, ADME
Wolthers, KC
Boucher, CAB
Gratama, JW
Budel, LM
van der Holt, B
van Loon, AM
Lowenberg, B
Verdonck, LF
Cornelissen, JJ
Citation: Jwj. Van Esser et al., Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation, BR J HAEM, 113(3), 2001, pp. 814-821
The dominant source of CD4(+) and CD8(+) T-cell activation in HIV infection is antigenic stimulation
Authors:
Stuart, JWTC
Hazebergh, MD
Hamann, D
Otto, SA
Borleffs, JCC
Miedema, F
Boucher, CAB
de Boer, RJ
Citation: Jwtc. Stuart et al., The dominant source of CD4(+) and CD8(+) T-cell activation in HIV infection is antigenic stimulation, J ACQ IMM D, 25(3), 2000, pp. 203-211
Authors:
Clevenbergh, P
Durant, J
Halfon, P
del Giudice, P
Mondain, V
Montagne, N
Schapiro, JM
Boucher, CAB
Dellamonica, P
Citation: P. Clevenbergh et al., Persisting long-term benefit of genotype-guided treatment for HIV-infectedpatients failing HAART. The Viradapt study: week 48 follow-up, ANTIVIR TH, 5(1), 2000, pp. 65-70
Authors:
Hazenberg, MD
Otto, SA
Stuart, JWTC
Verschuren, MCM
Borleffs, JCC
Boucher, CAB
Coutinho, RA
Lange, JMA
De Wit, TFR
Tsegaye, A
Van Dongen, JJM
Hamann, D
De Boer, RJ
Miedema, F
Citation: Md. Hazenberg et al., Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection, NAT MED, 6(9), 2000, pp. 1036-1042
Authors:
Back, NKT
van Wijk, A
Remmerswaal, D
van Monfort, M
Nijhuis, M
Schuurman, R
Boucher, CAB
Citation: Nkt. Back et al., In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors, AIDS, 14(1), 2000, pp. 101-102
Authors:
Van Vaerenbergh, K
Van Laethem, K
Albert, J
Boucher, CAB
Clotet, B
Floridia, M
Gerstoft, J
Hejdeman, B
Nielsen, C
Pannecouque, C
Perrin, L
Pirillo, MF
Ruiz, L
Schmit, JC
Schneider, F
Schoolmeester, A
Schuurman, R
Stellbrink, HJ
Stuyver, L
Van Lunzen, J
Van Remoortel, B
Van Wijngaerden, E
Vella, S
Witvrouw, M
Yerly, S
De Clercq, E
Desmyter, J
Vandamme, AM
Citation: K. Van Vaerenbergh et al., Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues, ANTIM AG CH, 44(8), 2000, pp. 2109-2117
Authors:
Maree, AFM
Keulen, W
Boucher, CAB
De Boer, RJ
Citation: Afm. Maree et al., Estimating relative fitness in viral competition experiments, J VIROLOGY, 74(23), 2000, pp. 11067-11072
Authors:
Frost, SDW
Nijhuis, M
Schuurman, R
Boucher, CAB
Brown, AJL
Citation: Sdw. Frost et al., Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection, J VIROLOGY, 74(14), 2000, pp. 6262-6268
Authors:
Sevin, AD
DeGruttola, V
Nijhuis, M
Schapiro, JM
Foulkes, AS
Para, MF
Boucher, CAB
Citation: Ad. Sevin et al., Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333, J INFEC DIS, 182(1), 2000, pp. 59-67
Authors:
Orendi, JM
Nottet, HSLM
de Vos, NM
Visser, MR
Snippe, H
Boucher, CAB
Verhoef, J
Citation: Jm. Orendi et al., Hydroxyurea interferes with antigen-dependent T-cell activation in vitro, EUR J CL IN, 30(2), 2000, pp. 162-166
Authors:
Hazenberg, MD
Stuart, JWTC
Otto, SA
Borleffs, JCC
Boucher, CAB
de Boer, RJ
Miedema, F
Hamann, D
Citation: Md. Hazenberg et al., T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART), BLOOD, 95(1), 2000, pp. 249-255
Authors:
Kamp, W
Schokker, J
Cambridge, E
De Jong, S
Schuurman, R
De Groot, T
Boucher, CAB
Citation: W. Kamp et al., Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results ofa Phase I/II study, ANTIVIR TH, 4(2), 1999, pp. 101-107
Authors:
Boucher, CAB
Citation: Cab. Boucher, HIV drug resistance tests are here to stay, CURR OPIN I, 12(1), 1999, pp. 27-32
Authors:
Been-Tiktak, AMM
Boucher, CAB
Brun-Vezinet, F
Joly, V
Mulder, JW
Jost, J
Cooper, DA
Moroni, M
Gatell, JM
Staszewski, S
Colebunders, R
Stewart, GJ
Hawkins, DA
Johnson, MA
Parkin, JM
Kennedy, DH
Hoy, JF
Borleffs, JCC
Citation: Amm. Been-tiktak et al., Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial, INT J ANT A, 11(1), 1999, pp. 13-21
Authors:
Stuart, JWTC
Schuurman, R
Burger, DM
Koopmans, PP
Sprengers, HG
Juttmann, JR
Richter, C
Meenhorst, PL
Hoetelmans, RMW
Kroon, FP
Bravenboer, B
Hamann, D
Boucher, CAB
Borleffs, JCC
Citation: Jwtc. Stuart et al., Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study), AIDS, 13(7), 1999, pp. F53-F58
Authors:
Nijhuis, M
Schuurman, R
de Jong, D
Erickson, J
Gustchina, E
Albert, J
Schipper, P
Gulnik, S
Boucher, CAB
Citation: M. Nijhuis et al., Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy, AIDS, 13(17), 1999, pp. 2349-2359
Authors:
Keulen, W
van Wijk, A
Schuurman, R
Berkhout, B
Boucher, CAB
Citation: W. Keulen et al., Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential, AIDS, 13(11), 1999, pp. 1343-1349
Authors:
Durant, J
Clevenbergh, P
Halfon, P
Delgiudice, P
Porsin, S
Simonet, P
Montagne, N
Boucher, CAB
Schapiro, JM
Dellamonica, P
Citation: J. Durant et al., Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial, LANCET, 353(9171), 1999, pp. 2195-2199
Risultati:
1-22
|